This trial involves the company’s third compound in clinical development to date. This Phase I trial will assess the safety, tolerability and pharmacokinetic profile of Volociximab.
Recently, Ophthotech enrolled its first patient in a Phase I complement inhibition trial for age-related macular degeneration (AMD) with its anti-C5 complement factor aptamer, ARC1905, in combination with an anti-VEGF agent. A dry AMD trial with ARC1905 is scheduled to commence in 2009.
Samir Patel, president and CEO of Ophthotech, said: “Initiating clinical development of Volociximab, our third compound, is an important milestone, as it demonstrates our commitment to developing and commercializing therapies for both wet and dry AMD in an accelerated manner.”